Loading...
•
Jun 30, 2023
Ardelyx Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023, and provided a business update.
Key Takeaways
Ardelyx reported a successful Q2 2023 with IBSRELA net sales revenue of $18.3 million, representing a 61% quarter-over-quarter growth. The company anticipates IBSRELA net sales revenue to be between $72 and $77 million for the full year 2023. They are also preparing for the potential approval and launch of XPHOZAH in Q4, with a user fee goal date of October 17, 2023. The company ended Q2 with $127.6 million in cash and investments.
IBSRELA net sales revenue reached $18.3 million in Q2 2023, a 61% increase compared to Q1 2023.
The company expects full-year 2023 IBSRELA net sales revenue to be between $72 and $77 million.
XPHOZAH is expected to launch in Q4, pending FDA approval, with a user fee goal date of October 17, 2023.
Ardelyx ended Q2 with $127.6 million in cash and investments.
Forward Guidance
Ardelyx expects full-year 2023 net product revenue for IBSRELA to be between $72.0 and $77.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...